Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/abbvie-inc-c0b93f23-6aae-45aa-858d-04ac387d1825">AbbVie </a>is successfully navigating the loss of exclusivity for its former blockbuster drug, Humira, driven by the robust growth of its next-generation immunology therapies, Skyrizi and Rinvoq, which are on track to collectively exceed Humira's peak sales.</li>
  <li>The company has built a diversified portfolio through strategic acquisitions, notably Allergan, which added leading aesthetics (Botox) and neuroscience franchises, reducing its reliance on immunology and providing new avenues for growth.</li>
  <li>
<a href="https://smartkarma.com/entities/abbvie-inc-c0b93f23-6aae-45aa-858d-04ac387d1825">AbbVie </a>remains a compelling investment for income-oriented investors, demonstrating a strong commitment to shareholder returns through a consistently growing dividend, supported by strong free cash flow generation. The company is a member of the S&amp;P Dividend Aristocrats Index.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
AbbVie is successfully navigating the loss of exclusivity for its former blockbuster drug, Humira, driven by the robust growth of its next-generation immunology therapies, Skyrizi and Rinvoq, which are on track to collectively exceed Humira's peak sales.
  The company has built a diversified portfolio through strategic acquisitions, notably Allergan, which added leading aesthetics (Botox) and neuroscience franchises, reducing its reliance on immunology and providing new avenues for growth.
  
AbbVie remains a compelling investment for income-oriented investors, demonstrating a strong commitment to shareholder returns through a consistently growing dividend, supported by strong free cash flow generation. The company is a member of the S&amp;P Dividend Aristocrats Index.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>AbbVie recently reported its financial results for the second quarter of 2025, showcasing both achievements and challenges.</li><li>AbbVie posted an adjusted earnings per share of $2.97, which surpassed their guidance midpoint by $0.11.</li><li>Total net revenues came in at $15.4 billion, exceeding expectations by over $400 million.</li></ul>

AbbVie recently reported its financial results for the second quarter of 2025, showcasing both achievements and challenges.AbbVie posted an adjusted earnings per share of $2.97, which surpassed their guidance midpoint by $0.11.Total net revenues came in at $15.4 billion, exceeding expectations by over $400 million.

AbbVie’s Skyrizi Surge: The Blockbuster Drug Defying Expectations & Dominating New Markets!

<ul><li>AbbVie’s reported discussions to acquire Gilgamesh Pharmaceuticals for approximately $1 billion mark the latest twist in the company’s aggressive M&A strategy, as it seeks new engines of growth beyond its ex-Humira platform.</li><li>Just days after raising its 2025 guidance on the strength of Skyrizi, Rinvoq and Vyalev — and outlining an $8-year runway driven by oncology, neuroscience, immunology and aesthetics — AbbVie is doubling down on psychiatric innovation.</li><li>Gilgamesh, a privately held developer of psychoplastogen-based therapies, has already joined forces with AbbVie on a co-development pact that could funnel up to $1.95 billion in milestone payments into novel mood-disorder treatments.</li></ul>

AbbVie’s reported discussions to acquire Gilgamesh Pharmaceuticals for approximately $1 billion mark the latest twist in the company’s aggressive M&A strategy, as it seeks new engines of growth beyond its ex-Humira platform.Just days after raising its 2025 guidance on the strength of Skyrizi, Rinvoq and Vyalev — and outlining an $8-year runway driven by oncology, neuroscience, immunology and aesthetics — AbbVie is doubling down on psychiatric innovation.Gilgamesh, a privately held developer of psychoplastogen-based therapies, has already joined forces with AbbVie on a co-development pact that could funnel up to $1.95 billion in milestone payments into novel mood-disorder treatments.

AbbVie’s $1 Billion Bet On Gilgamesh: The Neuroscience Acquisition That Could Change Everything!

<ul><li>AbbVie Inc. recently reported its results for the first quarter of 2025, showcasing strong performance across various therapeutic areas.</li><li>The company's adjusted earnings per share were $2.46, surpassing the guidance midpoint by $0.10.</li><li>Total net revenues stood at over $13.3 billion, a remarkable increase of roughly $550 million beyond expectations.</li></ul>

AbbVie Inc. recently reported its results for the first quarter of 2025, showcasing strong performance across various therapeutic areas.The company's adjusted earnings per share were $2.46, surpassing the guidance midpoint by $0.10.Total net revenues stood at over $13.3 billion, a remarkable increase of roughly $550 million beyond expectations.

AbbVie’s Bold Obesity Play Could Up Its Game In The GLP-1 Domain—Here’s What You Need to Know!

<ul><li>AbbVie Inc. concluded 2024 with robust performance metrics, highlighted by a notable return to growth, despite significant challenges such as the $5 billion U.S. Humira sales erosion due to biosimilar competition.</li><li>The company reported a total revenue of $56.3 billion, surpassing its initial guidance by over $2 billion, with adjusted earnings per share recorded at $10.12, which is $0.49 above their previously forecasted midpoint.</li><li>On a segmented basis, AbbVie's "ex-Humira" platform, consisting primarily of Skyrizi and Rinvoq, demonstrated substantial growth.</li></ul>

AbbVie Inc. concluded 2024 with robust performance metrics, highlighted by a notable return to growth, despite significant challenges such as the $5 billion U.S. Humira sales erosion due to biosimilar competition.The company reported a total revenue of $56.3 billion, surpassing its initial guidance by over $2 billion, with adjusted earnings per share recorded at $10.12, which is $0.49 above their previously forecasted midpoint.On a segmented basis, AbbVie's "ex-Humira" platform, consisting primarily of Skyrizi and Rinvoq, demonstrated substantial growth.

AbbVie Inc.: An Analysis Of Its Immunology Market Expansion, Oncology Pipeline & ADC Strategy!

United States

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including Multiple Sclerosis, Parkinson's, and Alzheimer's disease.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abbvie Inc (ABBV US)

Primer: AbbVie (ABBV UN) - Sep 2025

AbbVie is successfully navigating the loss of exclusivity for its former blockbuster drug, Humira, driven by the robust growth of its...

αSK

AbbVie’s Skyrizi Surge: The Blockbuster Drug Defying Expectations & Dominating New Markets!

AbbVie recently reported its financial results for the second quarter of 2025, showcasing both achievements and challenges. AbbVie posted an...

Baptista Research

AbbVie’s $1 Billion Bet On Gilgamesh: The Neuroscience Acquisition That Could Change Everything!

AbbVie’s reported discussions to acquire Gilgamesh Pharmaceuticals for approximately $1 billion mark the latest twist in the company’s aggressive...

Baptista Research

AbbVie’s Bold Obesity Play Could Up Its Game In The GLP-1 Domain—Here’s What You Need to Know!

AbbVie Inc. recently reported its results for the first quarter of 2025, showcasing strong performance across various therapeutic areas. The...

Baptista Research

AbbVie Inc.: An Analysis Of Its Immunology Market Expansion, Oncology Pipeline & ADC Strategy!

AbbVie Inc. concluded 2024 with robust performance metrics, highlighted by a notable return to growth, despite significant challenges such as the...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)